[en] Using high-resolution gamma spectrometry, we investigated the activity concentrations of thallium radioisotopes in a urine sample collected during a period of 24 h following nuclear medicine cardiac imaging. As part of a thallium stress test the subject of the study received a radiopharmaceutical preparation with 201Tl (activity 111 MBq). In order to assess whether the cardiac imaging procedure resulted in lymphocyte genome damage, we studied the frequency of sister chromatid exchanges (SCE) and lymphocyte cell kinetics in the blood samples collected before and after the cardiac imaging. The highest activity concentration (538960.9 ± 405.9 Bq/L_urine) was estimated for 201Tl, followed by 1770.54 ± 3.57 Bq/L_urine for 202Tl, and 422.035 ± 2.091 Bq/Lurine for 200Tl. The applied radiopharmaceutical contained 99.595 % of 201Tl, 0.078 % of 200Tl and 0.327 % of 202Tl. The estimated effective dose received through a single exposure to the radiopharmaceutical and calculated for a period of two days was mostly affected by 201Tl (0.0453 mSv). Due to its half-life of 12.2 days, the contribution of 202Tl (0.0008 mSv) to the effective dose was also significant. Results of the cytogenetic analysis indicate that a single diagnostic exposure to thallium caused an increase of SCE frequency and decrease of the proliferation rate index (PRI). Both parameters normalized steadily 14 days after the cardiac imaging procedure, which is also in accord with data obtained in previous studies. Our results indicate the presence of impurities in the radiopharmaceutical which should contain only 201Tl. This calls for a stricter process of quality control for radiopharmaceuticals used in nuclear medical diagnostic procedures. In this particular case, we emphasize 'contamination' with 202Tl, whose contribution to the effective dose cannot be ignored if one takes into account that it has the longest half-life of all three thallium radioisotopes detected in the urine sample.(author)